Premium
Tamoxifen: a novel treatment for primary biliary cirrhosis?
Author(s) -
Reddy A.,
Prince M.,
James O.F.,
Jain S.,
Bassendine M.F.
Publication year - 2004
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/j.1478-3231.2004.00920.x
Subject(s) - ursodeoxycholic acid , alkaline phosphatase , tamoxifen , medicine , primary biliary cirrhosis , gastroenterology , cholangiocyte , estrogen receptor , biliary cirrhosis , cirrhosis , endocrinology , chemistry , cancer , disease , breast cancer , enzyme , biochemistry , autoimmune disease
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease, which predominantly affects women. It is characterised histologically by necroinflammation of small intrahepatic bile ducts and biochemically by elevated serum alkaline phosphatase, levels of which at diagnosis predict survival. Ursodeoxycholic acid (UDCA) is the only treatment shown to improve liver biochemistry and survival. We report two patients with PBC who show a fall in serum alkaline phosphates levels whilst receiving tamoxifen therapy. Tamoxifen may exert this effect, which warrants further study, either via cholangiocyte estrogen receptors, inhibiting cholangiocyte proliferation and inducing apoptosis or by activating pregnane X receptor, analogous to the mode of action of UDCA.